Onexton is a U.S. prescription gel combining clindamycin phosphate 1.2% (equivalent to 1% clindamycin) with benzoyl peroxide 3.75% for topical acne treatment in patients 12 years and older. Its premixed gel and exact benzoyl peroxide strength distinguish it from Acanya 1.2%/2.5%, from 1.2%/5% gels and from single-ingredient clindamycin. Explore the two-active gel category for the wider comparison.
Onexton has product-specific instructions and restrictions. The current U.S. labeling lists hypersensitivity to clindamycin, lincomycin, benzoyl peroxide or formulation components and histories of regional enteritis, ulcerative colitis or antibiotic-associated colitis as contraindications. These restrictions must not be described as routine precautions merely because the gel is used on the skin.
This page focuses on Onexton identification, its labeled formulation and age group, warnings, pharmacy verification and differences from neighboring acne brands. The presence of an official label does not confirm real-time inventory at a particular U.S. pharmacy, nor does it authorize substitution for a different prescription gel.
Onexton is a premixed topical gel with 12 mg clindamycin phosphate per gram (equivalent to 10 mg clindamycin) and 37.5 mg benzoyl peroxide per gram. The clindamycin phosphate strength of 1.2% reflects the salt; it is not a second antibiotic or a higher clinically equivalent dose than the 1% base statement.
The brand is indicated for acne vulgaris at age 12 years and older, and the Onexton label gives a once-daily face-application framework. Those instructions are specific to this product and do not transfer automatically to Acanya, DUAC, plain clindamycin or a different combination.
The Onexton labeling identifies a premixed pump dispenser and has specific package and use instructions. A pharmacy listing should be checked for the complete formula and presentation rather than a generic photograph of acne gel.
Product packaging, quantity and manufacturer labeling are separate facts from live pharmacy stock. The fact that a presentation appears on DailyMed does not establish that it is currently in inventory at a particular location.
Onexton contains 3.75% benzoyl peroxide while Acanya contains 2.5%, alongside the same labeled 1.2% clindamycin phosphate concentration. These are not the same complete FDA-labeled product. Product vehicle, packaging, age indications and directions should be reviewed separately rather than inferred from the shared antibiotic.
A difference in printed percentage alone does not establish that Onexton gives better results for a particular patient or that the products are substitutable. The Acanya brand guide identifies its own formula; any switch requires pharmacist assessment and potentially prescriber authorization.
The manufacturer label provides directions for applying the product to skin and avoiding the eyes, mouth and vagina. The clinician’s instructions should be followed; the amount and frequency should not be increased to try to accelerate acne improvement.
Common practical concerns include dryness, redness, peeling and irritation. Benzoyl peroxide can bleach fabric. Patients should ask before combining it with additional irritating topical products.
A pharmacy may surface several clindamycin/benzoyl peroxide entries with different ratios or quantities. Ask the pharmacist to compare the active ingredients, percentages, route and intended packaging to the prescription.
The preferred generic under a plan may not have the same exact formula as a requested brand. Pharmacy benefit information and substitution rules should be checked without assuming one combination will be covered or medically appropriate.
Onexton Gel is contraindicated in patients who have shown hypersensitivity to clindamycin, benzoyl peroxide, lincomycin or any component of the formulation. It is also contraindicated in patients with histories of regional enteritis, ulcerative colitis or antibiotic-associated colitis. A history of one of these bowel conditions is not simply a suggestion to monitor more closely; it appears under the formal contraindications in the label.
Systemic absorption of topical clindamycin has been demonstrated. The label warns that diarrhea, bloody diarrhea and severe colitis can occur and states that Onexton should be discontinued if significant diarrhea occurs; prompt clinical assessment is important. Other concerns include skin irritation, excessive UV exposure and additive irritation with other topical acne products. Benzoyl peroxide is relevant to antibiotic-resistance management, but it does not remove these safety restrictions.
Ask the pharmacy to confirm Onexton by its two active ingredients, both concentrations, topical gel route, premixed pump presentation and exact amount prescribed. A listing for clindamycin/benzoyl peroxide 1.2%/5% is not the same formulation as Onexton 1.2%/3.75%. The prescription guide explains how unclear entries should be resolved.
If the pharmacy offers a different manufacturer or an alternate formulation, request confirmation of the specific approved drug and any therapeutic-equivalence/substitution determination required. For a remote seller, verify licensing and pharmacist access through the online pharmacy checklist; do not treat a product photo as evidence of stock.
The amount a patient pays for Onexton can depend on brand versus generic status, package quantity, network status, formulary preferences, deductibles and dispensing terms. No static dollar quote can represent all pharmacies or plans. Start with topical clindamycin cost factors for a route-specific checklist.
For Onexton, request a pharmacy quote on the same 1.2%/3.75% pump and patient-specific insurance terms. The insurance guide explains prior authorization and preferred-product restrictions; compare a different gel only after its clinical identity is verified.
The Onexton dispensing check begins with the full 1.2% clindamycin phosphate / 3.75% benzoyl peroxide pump identity. The clinician and pharmacist must distinguish it from any other clindamycin-containing acne medicine, including products that share only one ingredient or a similar percentage.
For Onexton, an unexpected 2.5% or 5% benzoyl peroxide value changes the formula rather than merely the packaging. Check the actual pump and both ingredient concentrations before a prescription is filled.
| Check | Brand identity | What to ask the pharmacy |
|---|---|---|
| Ingredient formula | clindamycin phosphate 1.2% and benzoyl peroxide 3.75% | Does the dispensed item match the prescription? |
| Route | Topical skin use only | Is this a prescription acne gel, not oral or vaginal medication? |
| Brand/generic | Brand label; any substitutes require verification | Is the proposed alternative appropriate and permitted? |
| Pack and quantity | Manufacturer-labeled package; verify current presentation | Which package and quantity will be dispensed? |
| Cost | Plan or cash quote varies | What is the full current patient price? |
Contact the prescriber about persistent or substantial redness, swelling, peeling or burning, particularly when multiple acne products are being used. Stop use and seek urgent assistance for signs of a serious allergic reaction, such as breathing difficulty or swelling of the face or throat. Significant diarrhea, especially with abdominal pain or blood, also requires prompt assessment because clindamycin can cause colitis.
A pregnancy-related question, a history of antibiotic-associated bowel disease or any planned change in product should be reviewed before a fill or regimen change. Do not independently increase the frequency or combine extra acne medications in an attempt to speed improvement.
Onexton contains clindamycin phosphate 1.2%, equivalent to 1% clindamycin, and benzoyl peroxide 3.75% in a prescription topical gel.
No. Onexton includes a prescription antibiotic, so dispensing requires an appropriate valid U.S. prescription.
No. Onexton contains 3.75% benzoyl peroxide, while Acanya is labeled with 2.5%. They have distinct product labels and are not automatic substitutes.
The U.S. label lists histories of regional enteritis, ulcerative colitis and antibiotic-associated colitis as formal contraindications.
Yes. Topical clindamycin can be systemically absorbed, and the label warns of diarrhea and serious colitis. Significant diarrhea needs prompt professional assessment.
Its U.S. labeled acne indication is for patients aged 12 years and older. A clinician must assess any individual treatment.
Not independently. The benzoyl peroxide concentration differs. A pharmacist and prescriber must assess the exact product and lawful substitution.
No. DailyMed is a source of product and safety information, not a live inventory feed. Ask the dispensing pharmacy about the precise package.
Yes. Additional exfoliating, drying or abrasive acne products may produce cumulative irritation. Review your complete regimen with the prescriber or pharmacist.